drugset / Trial / NCT01262196

Phase IIb Study of MP4OX in Traumatic Hemorrhagic Shock Patients

NCT01262196 ↗

Phase 2 Completed 348 enrolled Sangart
RandomizedParallel-groupQuadruple-blindTreatment

Summary

MP4OX is a novel oxygen therapeutic agent being developed as an ischemic rescue therapy to enhance perfusion and oxygenation of tissues at risk during hemorrhagic shock. MP4OX is a pegylated hemoglobin-based colloid. Due to its molecular size and unique oxygen dissociation characteristics, MP4OX targets delivery of oxygen to ischemic tissues. This study will evaluate the safety and efficacy of MP4OX treatment in trauma patients suffering from lactic acidosis due to severe hemorrhagic shock. The study hypothesis is that MP4OX will reverse the lactic acidosis by enhancing perfusion and oxygenation of ischemic tissues and thereby prevent and reduce the duration of organ failure and improve outcome in these patients.

Timeline

Start
2011-05
Primary completion
2012-10
Completion
2012-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject MP4OX Protein / enzyme biologic 250 ml —

Indications